Technological development at the boundaries of the firm: A knowledge-based examination in drug development

Strategic Management Journal

Volumn 33, Issue 9, 2012, Pages 1016-1036

  MacHer, Jeffrey T ^a   Boerner, Christopher ^b  

^a GEORGETOWN UNIVERSITY   (United States)

^b SEATTLE GENETICS INC   (United States)

Author keywords

firm boundaries; knowledge based view (KBV); learning economies; pharmaceutical industry; problem solving

Indexed keywords

DRUG DEVELOPMENT; EMPIRICAL EXAMINATION; FIRM BOUNDARIES; KNOWLEDGE DEVELOPMENT; KNOWLEDGE-BASED VIEWS; LEARNING ECONOMIES; PHARMACEUTICAL INDUSTRY; TECHNOLOGICAL DEVELOPMENT;

KNOWLEDGE BASED SYSTEMS; PROBLEM SOLVING;

INDUSTRY;

EID: 84863728796     PISSN: 01432095     EISSN: 10970266     Source Type: Journal    
DOI: 10.1002/smj.1956     Document Type: Article

References (65)

1. Abrantes-Metz RM, Adams CP, Metz A,. 2004. Pharmaceutical development phases: a duration analysis. FTC Bureau of Economics Working paper no. 274. Federal Trade Commission, Washington, D.C.
2. Argote L,. 1999. Organizational Learning: Creating, Retaining and Transferring Knowledge. Kluwer Academic: Boston, MA.
3. Armour HO, Teece DJ,. 1980. Vertical integration and technological innovation. Review of Economics and Statistics 62 (3): 470-474.
4. Arora A, Gambardella A,. 1994. The changing technology of technological change: general and abstract knowledge and the division of innovative labor. Research Policy 23 (5): 523-532.
5. Azoulay P,. 2004. Capturing knowledge within and across firm boundaries: evidence from clinical development. American Economics Review 94 (5): 1591-1612. (Pubitemid 40465228)
6. Baum JAC, Li SX, Usher JM,. 2000. Making the next move: how experiential and vicarious learning shape the locations of chains' acquisitions. Administrative Science Quarterly 45: 766-801. (Pubitemid 33231595)
7. Baum JAC, Oliver C,. 1991. Institutional linkages and organizational mortality. Administrative Science Quarterly 36: 187-218.
8. Benkard LC,. 1999. Learning and forgetting: the dynamics of aircraft production. American Economic Review 90 (4): 1034-1054.
9. Brown SL, Eisenhardt KM,. 1995. Product development: past research, present findings, and future directions. Academy of Management Review 20 (2): 343-378.
10. Carroll GR, Hannan MT,. 2000. The Demography of Corporations and Industries. Princeton University Press: Princeton, NJ.
11. Chesbrough HW, Teece DJ,. 1996. When is virtual virtuous? Organizing for innovation. Harvard Business Review 74 (1): 65-73.
12. Cockburn IM, Henderson RM,. 2001. Scale and scope in drug development: unpacking the advantage of size in pharmaceutical research. Journal of Health Economics 20: 1033-1057. (Pubitemid 33010787)
13. Cohen WM, Levinthal DA,. 1990. Absorptive capacity: a new perspective on learning and innovation. Administrative Science Quarterly 35 (1): 128-152.
14. Conner KR,. 1991. A historical comparison of resource-based theory and five schools of thought within industrial organization economics: do we have a new theory of the firm? Journal of Management 17 (1): 121-154.
15. Conner KR, Prahalad CK,. 1996. A resource-based theory of the firm: knowledge vs. opportunism. Organization Science 7 (5): 477-501.
16. D'Aveni RA, Ravenscraft DJ,. 1994. Economies of integration versus bureaucracy costs: does vertical integration improve performance? Academy of Management Journal 37 (5): 1167-1206.
17. Danzon PM, Nicholson S, Pereira NS,. 2005. Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances. Journal of Health Economics 24 (2): 317-339. (Pubitemid 40249770)
18. Dranove D, Meltzer D,. 1994. Do important drugs reach the market sooner? RAND Journal of Economics 25: 402-423.
19. Ethiraj SK, Levinthal D,. 2004. Bounded rationality and the search for organizational architecture: an evolutionary perspective on the design of organizations and their evolvability. Administrative Science Quarterly 49: 404-437. (Pubitemid 40366657)
20. Fernandes R, Simon HA,. 1999. A study of how individuals solve complex and ill-structured problems. Policy Sciences 32 (3): 225-245.
21. Fleming L, Sorenson O,. 2004. Science as a map in technological search. Strategic Management Journal, August-September Special Issue 25: 909-928.
22. Gambardella A,. 1995. Science and Innovation: The U.S. Pharmaceutical Industry During the 1980s. Cambridge University Press: Cambridge, UK.
23. Grabowski H, Vernon M,. 1990. A new look at the returns and risks to pharmaceutical R&D. Management Science 36 (7): 804-882.
24. Grant RM,. 1996. Toward a knowledge-based theory of the firm. Strategic Management Journal, Winter Special Issue 17: 109-122.
25. Hamilton BH, Nickerson JA,. 2003. Correcting for endogeneity in strategic management research. Strategic Organization 1 (1): 53-80.
26. Hammond TH, Miller G,. 1985. A social choice perspective on expertise and authority in bureaucracy. American Journal of Political Science 29: 1-28.
27. Haveman HA,. 1993. Follow the leader: mimetic isomorphism and entry into new markets. Administrative Science Quarterly 38: 564-592.
28. Heckman JJ,. 1979. Sample selection bias as a specification error. Econometrica 47 (1): 153-162.
29. Henderson R, Cockburn I,. 1994. Measuring competence? Exploring firm effects in pharmaceutical research. Strategic Management Journal, Winter Special Issue 15: 63-84.
30. Henderson R, Cockburn I,. 1996. Scale, scope and spillovers: the determinants of research productivity in drug discovery. RAND Journal of Economics 27 (1): 32-59. (Pubitemid 126316948)
31. Hsieh C, Nickerson JA, Zenger TR,. 2007. Opportunity discovery, problem solving and a theory of the entrepreneurial firm. Journal of Management Studies 44 (7): 1255-1277.
32. King G, Tomz M, Wittenberg J,. 2000. Making the most of statistical analyses: improving interpretation and presentation. American Journal of Political Science 44 44 (2): 347-361.
33. Kogut B, Zander U,. 1992. Knowledge of the firm, combinative capabilities, and the replication of technology. Organization Science 3 (3): 383-397.
34. Kogut B, Zander U,. 1996. What firms Do? Coordination, identity and learning. Organization Science 7 (5): 502-518.
35. Leonard-Barton D,. 1992. Core capabilities and core rigidities: a paradox in managing new product development. Strategic Management Journal, Summer Special Issue 13: 111-125.
36. Levinthal D,. 1997. Adaptation on rugged landscapes. Management Science 43 (7): 934-950. (Pubitemid 127600362)
37. Lieberman MB, Montgomery DB,. 1988. First-mover advantages. Strategic Management Journal, Summer Special Issue 9: 41-58.
38. Macher JT,. 2006. Technological development and the boundaries of the firm: a knowledge-based examination in semiconductor manufacturing. Management Science 52 (6): 826-843.
39. Macher JT, Boerner CS,. 2006. Experience and scale and scope economies: trade-offs and performance in drug development. Strategic Management Journal 27 (9): 845-865. (Pubitemid 44257292)
40. Malerba F, Orsenigo L,. 2001. Innovation and market structure in the dynamics of the pharmaceutical industry and biotechnology: towards a history-friendly model. Industrial and Corporate Change 11 (4): 667-703. (Pubitemid 34990158)
41. Malmgren HB,. 1961. Information, expectations and the theory of the firm. Quarterly Journal of Economics 75: 399-421.
42. March JG,. 1988. Decisions in Organizations. Basil Blackwell: Oxford, U.K.
43. Mathieu M,. 1997. New Drug Development: A Regulatory Overview (4th edn). Parexel International Corporation: Waltham, MA.
44. Mayer KJ, Salomon R,. 2006. Capabilities, contractual hazards and governance: integrating resource-based and transaction cost frameworks. Academy of Management Journal 49 (5): 942-959. (Pubitemid 44787926)
45. McGee P,. 2005. Virtual discovery and development. Drug Discovery & Development 8 (11): S3-S8.
46. Miller KL, Pryce SL,. 1999. Better, faster, worldwide too: update on pharmaceutical contract support organizations. Hambrecht & Quist LLC Industry Report: San Francisco, CA.
47. Mitchell W, Shaver JM, Yeung B,. 1994. Foreign entrant survival and foreign market share: Canadian companies' experience in United States medical sector markets. Strategic Management Journal 15 (7): 555-567.
48. Monteverde K,. 1995. Technical dialog as an incentive for vertical integration in the semiconductor industry. Management Science 41 (10): 1624-1638.
49. Nelson RR, Winter SG,. 1982. An Evolutionary Theory of Economic Change. Belknap Press: Cambridge, MA.
50. Nickerson JA, Zenger TR,. 2004. A knowledge-based theory of governance choice-a problem-solving approach. Organization Science 15 (6): 617-632. (Pubitemid 40031071)
51. OTA. 1993. Pharmaceutical R&D: costs, risks and rewards. Office of Technology Assessment: Washington, DC.
52. Parmigiani A,. 2007. Why do firms both make and buy? An investigation of concurrent sourcing. Strategic Management Journal 28 (3): 285-311.
53. Parmigiani A, Mitchell W,. 2009. Complementarity, capabilities, and the boundaries of the firm: the impact of within-firm and interfirm expertise on concurrent sourcing of complementary components. Strategic Management Journal 30 (10): 1065-1091.
54. PhRMA. 1999. Industry Profile. Pharmaceutical Manufacturers Association: Washington, DC.
55. Poppo L, Zenger T,. 1998. Testing alternative theories of the firm: transaction cost, knowledge-based, and measurement explanations for make-or-buy decisions in information services. Strategic Management Journal 19 (9): 853-877. (Pubitemid 128469379)
56. Simon HA,. 1962. The architecture of complexity. Proceedings of the American Philosophical Society 106 (6): 467-482.
57. Simon HA,. 1973. The structure of ill-structured problems. Artificial Intelligence 4: 181-191.
58. Spilker B,. 1989. Multinational Drug Companies: Issues in Drug Discovery and Development. Raven Press: New York.
59. Teece DJ,. 1996. Firm organization, industrial structure, and technological innovation. Journal of Economic Behavior and Organization 31 (2): 193-224. (Pubitemid 126166637)
60. Thiers FA, Sinskey AJ, Berndt ER,. 2008. Trends in the globalization of clinical trials. Nature Reviews 7: 13-14.
61. Wheelwright SC, Clark KB,. 1992. Creating project plans to focus product development. Harvard Business Review 70 (2): 70-82.
62. Wiggins S,. 1981. Product quality regulation and new drug introductions: some new evidence from the 1970s. Review of Economics and Statistics 63 (4): 615-619.
63. Williamson OE,. 1991. Comparative economic organization: the analysis of discrete structural alternatives. Administrative Science Quarterly 36: 269-296.
64. Woodcock J,. 1997. An FDA perspective on the drug development process. Food and Drug Law Journal 52: 145-150. (Pubitemid 27264311)
65. Zucker LG, Darby MR, Armstrong JS,. 2002. Commercializing knowledge: university science, knowledge capture, and firm performance in biotechnology. Management Science 48 (1): 138-153. (Pubitemid 34440352)